Bristol Myers Squibb announced the deployment of its second NVIDIA DGX SuperPOD supercomputer cluster built on eight DGX Vera Rubin NVL72 systems to accelerate drug discovery research.

Key Details

• Deploys eight DGX Vera Rubin NVL72 systems delivering up to 10x performance per megawatt.
• Provides unified AI platform access across all BMS global research sites.
• Integrates NVIDIA BioNeMo Agent Toolkit and NVIDIA Mission Control for biological AI workflows.

In This Story